|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC18B1 |
Gene summary for SLC18B1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC18B1 | Gene ID | 116843 |
| Gene name | solute carrier family 18 member B1 | |
| Gene Alias | C6orf192 | |
| Cytomap | 6q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6NT16 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116843 | SLC18B1 | LZE8T | Human | Esophagus | ESCC | 3.21e-02 | 3.67e-02 | 0.067 |
| 116843 | SLC18B1 | LZE24T | Human | Esophagus | ESCC | 1.26e-10 | 4.00e-01 | 0.0596 |
| 116843 | SLC18B1 | P1T-E | Human | Esophagus | ESCC | 4.68e-03 | 3.09e-01 | 0.0875 |
| 116843 | SLC18B1 | P2T-E | Human | Esophagus | ESCC | 2.30e-10 | 1.57e-01 | 0.1177 |
| 116843 | SLC18B1 | P8T-E | Human | Esophagus | ESCC | 5.75e-08 | 1.72e-01 | 0.0889 |
| 116843 | SLC18B1 | P9T-E | Human | Esophagus | ESCC | 6.22e-03 | -7.14e-03 | 0.1131 |
| 116843 | SLC18B1 | P10T-E | Human | Esophagus | ESCC | 6.55e-06 | 7.35e-03 | 0.116 |
| 116843 | SLC18B1 | P11T-E | Human | Esophagus | ESCC | 4.24e-02 | 8.94e-02 | 0.1426 |
| 116843 | SLC18B1 | P15T-E | Human | Esophagus | ESCC | 3.43e-05 | 5.58e-02 | 0.1149 |
| 116843 | SLC18B1 | P16T-E | Human | Esophagus | ESCC | 2.98e-15 | 1.04e-01 | 0.1153 |
| 116843 | SLC18B1 | P21T-E | Human | Esophagus | ESCC | 1.22e-09 | 8.32e-02 | 0.1617 |
| 116843 | SLC18B1 | P22T-E | Human | Esophagus | ESCC | 2.73e-08 | 1.65e-02 | 0.1236 |
| 116843 | SLC18B1 | P23T-E | Human | Esophagus | ESCC | 2.41e-20 | 7.38e-01 | 0.108 |
| 116843 | SLC18B1 | P24T-E | Human | Esophagus | ESCC | 1.47e-06 | 2.27e-02 | 0.1287 |
| 116843 | SLC18B1 | P26T-E | Human | Esophagus | ESCC | 2.04e-05 | 2.15e-02 | 0.1276 |
| 116843 | SLC18B1 | P27T-E | Human | Esophagus | ESCC | 6.25e-15 | 1.31e-01 | 0.1055 |
| 116843 | SLC18B1 | P28T-E | Human | Esophagus | ESCC | 7.21e-03 | 2.72e-02 | 0.1149 |
| 116843 | SLC18B1 | P30T-E | Human | Esophagus | ESCC | 5.12e-08 | 1.69e-01 | 0.137 |
| 116843 | SLC18B1 | P36T-E | Human | Esophagus | ESCC | 6.49e-04 | 3.48e-02 | 0.1187 |
| 116843 | SLC18B1 | P37T-E | Human | Esophagus | ESCC | 2.32e-09 | 8.14e-02 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC18B1 | SNV | Missense_Mutation | novel | c.1135N>T | p.Leu379Phe | p.L379F | Q6NT16 | protein_coding | deleterious(0.03) | benign(0.25) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| SLC18B1 | SNV | Missense_Mutation | c.670N>C | p.Gly224Arg | p.G224R | Q6NT16 | protein_coding | tolerated(0.23) | benign(0.024) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SLC18B1 | insertion | Frame_Shift_Ins | novel | c.113_114insT | p.Ser39IlefsTer25 | p.S39Ifs*25 | Q6NT16 | protein_coding | TCGA-A2-A3XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD | ||
| SLC18B1 | insertion | In_Frame_Ins | novel | c.1310_1311insTTGTGT | p.Lys437delinsAsnCysVal | p.K437delinsNCV | Q6NT16 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SLC18B1 | insertion | Nonsense_Mutation | novel | c.1309_1310insTTGCTGTGGTTCCTCTGCTGAGCTTGGTTCAGTAGAA | p.Lys437IlefsTer12 | p.K437Ifs*12 | Q6NT16 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SLC18B1 | SNV | Missense_Mutation | c.673N>A | p.Glu225Lys | p.E225K | Q6NT16 | protein_coding | tolerated(1) | benign(0.003) | TCGA-C5-A1MF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC18B1 | SNV | Missense_Mutation | c.233G>A | p.Cys78Tyr | p.C78Y | Q6NT16 | protein_coding | deleterious(0) | benign(0.145) | TCGA-C5-A7CJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| SLC18B1 | SNV | Missense_Mutation | c.192G>C | p.Lys64Asn | p.K64N | Q6NT16 | protein_coding | tolerated(0.13) | benign(0.118) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| SLC18B1 | SNV | Missense_Mutation | c.116N>T | p.Ser39Leu | p.S39L | Q6NT16 | protein_coding | tolerated(0.12) | benign(0.017) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SLC18B1 | SNV | Missense_Mutation | rs200561155 | c.89N>T | p.Ser30Leu | p.S30L | Q6NT16 | protein_coding | deleterious(0) | benign(0.279) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |